
Scade Medical handheld Skin Cancer Diagnotics Scanner is raising funding for Clinical Trials
Scade Medical, (http://scademedical.com) was founded in 2013 by Dr. Ofir Aharon and Mr. Gabi Mizrahi along with first two investors Mr. Shlomi Swissa and Mr.

FDA Approves Teva’s First and Only Digital Inhaler with Built-In Sensors
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir® Digihaler™ (albuterol sulfate 117

Point of Care Blood Test Co. Sight Diagnostics raises $28m on Start of Marketing of Malaria to Developing Countries
Sight Diagnostics (SightDX), a portfolio company of Anatomy, Clal Biotechnology’s investment fund for medical devices, had raised $28 million. When the round is completed, Anatomy’s

Powermat Wireless Charging Founder Ran Poliakine Launches Innovation Center to Advance Early Stage Wearable Technologies
Ran Poliakine, founder and former CEO of Powermat, has established a new Innovation Center designed to foster and develop new and emerging wearable technologies. The Innovation

RenalSense Conducts Pilot Study on ICU Patient Monitoring at U of Pittsburgh Medical Center
RenalSense® is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of Professor

BrainsWay Selected for USA FDA Innovation Challenge to tackle Opioid Addiction
BrainsWay‘s deep transcranial magnetic stimulation (Deep TMS) system was one of only eight medical devices selected by the U.S. Food and Drug Administration (FDA) from

Pepticom’s AI Discovered 53 Novel Immune-Mmodulators
Pepticom was honored with an image from their article on this December’s Journal of Immunology. The image is taken from Pepticom’s latest article “Computationally Designed Bispecific

Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game!
While current immunotherapies offer promise to previously untreatable cancers, they only work in a small percentage of patients with certain types of cancer. Scientists have

Enlivex Therapeutics merged into NASDAQ-based Co-Bioblast Pharma Ltd, of Dahlia Meggido
Bioblast Pharma Ltd. (Nasdaq:ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the